tetano
Editor, Senior Moderator
Monaldi Arch Chest Dis
. 2023 Nov 3.
doi: 10.4081/monaldi.2023.2784. Online ahead of print. COVID myocarditis: a review of the literature
Angelica Cersosimo[SUP] 1 [/SUP], Mattia Di Pasquale[SUP] 2 [/SUP], Gianmarco Arabia[SUP] 3 [/SUP], Marco Metra[SUP] 4 [/SUP], Enrico Vizzardi[SUP] 5 [/SUP]
Affiliations
Myocarditis is a potentially fatal complication of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis appears to have distinct inflammatory characteristics that distinguish it from other viral etiologies. COVID-19 myocarditis can present with symptoms ranging from dyspnea and chest pain to acute heart failure and death. It is critical to detect any cases of myocarditis, especially fulminant myocarditis, which can be characterized by signs of heart failure and arrhythmias. Serial troponins, echocardiography, and electrocardiograms should be performed as part of the initial workup for suspected myocarditis. The second step in detecting myocarditis is cardiac magnetic resonance imaging and endomyocardial biopsy. Treatment for COVID-19 myocarditis is still debatable; however, combining intravenous immunoglobulins and corticosteroids may be effective, especially in cases of fulminant myocarditis. Overall, more research is needed to determine the incidence of COVID-19 myocarditis , and the use of intravenous immunoglobulins and corticosteroids in combination requires large randomized controlled trials to determine efficacy. The purpose of this review is to summarize current evidence on the subject. This review aims to summarise current evidence on this topic.
. 2023 Nov 3.
doi: 10.4081/monaldi.2023.2784. Online ahead of print. COVID myocarditis: a review of the literature
Angelica Cersosimo[SUP] 1 [/SUP], Mattia Di Pasquale[SUP] 2 [/SUP], Gianmarco Arabia[SUP] 3 [/SUP], Marco Metra[SUP] 4 [/SUP], Enrico Vizzardi[SUP] 5 [/SUP]
Affiliations
- PMID: 37930657
- DOI: 10.4081/monaldi.2023.2784
Myocarditis is a potentially fatal complication of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis appears to have distinct inflammatory characteristics that distinguish it from other viral etiologies. COVID-19 myocarditis can present with symptoms ranging from dyspnea and chest pain to acute heart failure and death. It is critical to detect any cases of myocarditis, especially fulminant myocarditis, which can be characterized by signs of heart failure and arrhythmias. Serial troponins, echocardiography, and electrocardiograms should be performed as part of the initial workup for suspected myocarditis. The second step in detecting myocarditis is cardiac magnetic resonance imaging and endomyocardial biopsy. Treatment for COVID-19 myocarditis is still debatable; however, combining intravenous immunoglobulins and corticosteroids may be effective, especially in cases of fulminant myocarditis. Overall, more research is needed to determine the incidence of COVID-19 myocarditis , and the use of intravenous immunoglobulins and corticosteroids in combination requires large randomized controlled trials to determine efficacy. The purpose of this review is to summarize current evidence on the subject. This review aims to summarise current evidence on this topic.